Despre Dexcom

June
2017

Dexcom Receives FDA Approval of G5 Mobile App for Android Devices

Android users now have access to the free app for the Dexcom G5 Mobile CGM System. The Dexcom G5 Mobile CGM System is the first and only CGM platform available for Android in the United States.

January
2017

The Dexcom G5 Mobile CGM System is approved under Medicare

Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as „Durable Medical Equipment”. Dexcom is the first CGM system that falls within this classification.

December
2016

The Non-Adjunctive Label for the Dexcom G5 Mobile CGM System is approved by the FDA Advisory Committee

The proposed non-adjunctive indication for the Dexcom G5 Mobile CGM system is approved by the FDA. This indication designates the G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions.

September
2015

Dexcom G5 Mobile CGM System launched

The Dexcom G5 Mobile CGM System became the first and only fully mobile CGM system to allow adults and children as young as two years old the convenience of monitoring their glucose levels from a compatible smart device. It also gave patients the option to safely share their glucose data with others.

January
2015

Dexcom G4 PLATINUM CGM System with Share launched

The Share feature for the G4 PLATINUM CGM System gave patients the option to share their glucose information with up to five followers through Dexcom Share and Follower apps on their smart devices via a secure wireless connection.

October
2012

Dexcom G4 PLATINUM System launched

The G4 PLATINUM’s overall accuracy and ease of use set a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available at the time.

November
2009

Dexcom SEVEN® PLUS CGM System launched

The SEVEN® PLUS System launched as Dexcom’s third generation device designed to help people with diabetes better manage their glucose levels.

September 8
2008

JDRF landmark study in CGM

Study data presented by the Juvenile Diabetes Research Foundation (JDRF) at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) showed the use of CGM to be effective in the management of type 1 diabetes.

May 31
2007

SEVEN® System launched

Dexcom launched the SEVEN® CGM System, the first CMG system approved for up to seven days of continual use.

March 27
2006

STS CGM System launched

Dexcom launched the first generation continuous glucose monitor designed to help people with diabetes more conveniently and effectively manage their blood sugar levels.

April 14
2005

Dexcom announced its IPO

The initial public offering (IPO) for Dexcom was announced on the NASDAQ Stock Market under DXCM.

2004

Short-term sensor

Dexcom’s short-term sensor program was created.

1999 –
2003

Research on long-term continuous glucose sensing

Three generations of Dexcom’s long-term implantable sensors were developed and studied in humans.

1999

Dexcom was founded

Dexcom was founded based on the groundbreaking research of Dr. Stuart J. Updike and George P. Hicks in 1967—implantable, long-performing glucose sensors that the body would not reject. Dr. Updike joined Dexcom that year to continue CGM innovation.